Breaking News
22 hours ago
Vaibhavi M.

Glenmark moves a HER2-targeted ADC into Phase 3 for platinum-resistant ovarian cancer, raising GMP and process validation considerations for ADC manufacturing at scale.
Vaibhavi M.

Syngene names Siddharth Mittal MD and CEO; his 13-year CFO tenure at Biocon shapes expectations for CDMO capacity and partnership strategy.
Vaibhavi M.

FDA CBER issued a March 2026 approval letter for GlaxoSmithKline's Fluarix, shifting the seasonal strain update timeline earlier than prior years.
Vaibhavi M.

EMA formalises a women's health initiative across four workstreams, with clinical trial design and labelling obligations set for review ahead of a September workshop.
Vaibhavi M.
